

FORM PTO-1449		DOCKET NO.:		SERIAL NO.:			
INFORMATION DISCLOSURE		57151-CON(46453)		- 10/783,615			
STATEMENT		APPLICANT(S):					
		Salim Yusuf					
		FILING DATE:		GROUP NO.:			
		Herewith		1614 (Presumed)			
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION YES/NO
KW	BA	WO 01/15674 A2	08/03/2001	PCT	A61K	31/00	Yes
	BB	WO 01/15673 A2	08/03/2001	PCT	A61K	31/00	Yes
	BC	DE 43 08 504 A1	22/09/1994	GERMANY	A61K	31/275	No
KW	BD	EP 0 331 014 A2	06/09/1989	EUROPE	A61K	37/64	No
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)							
KW	CA	Janka, et al., "Metabolic effects of ramipril treatment in hypersensitive subjects with non-insulin-dependent diabetes mellitus," Arzneimittel-Forschung, Germany, Vol. 40, No. 4, April 1990, pp. 432-435, XP001109698.					
	CB	"Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators," The Lancet, England, 22 January 2000, Vol. 355, No. 9200, pp. 253-259, XP002232380.					
	CC	Krützfeldt, et al., "Ramipril increases the protein level of skeletal muscle IRS-1 and alters protein tyrosine phosphatase activity in spontaneously hypertensive rats," Naunyn-Schmiedeberg's Archives of Pharmacology, Vol. 362, No.1, July 2000, pp. 1-6, XP001148413.					
	CD	Galletti, et al., "Controlled study of the effect of angiotensin converting enzyme inhibition versus calcium-entry blockade on insulin sensitivity in overweight hypertensive patients: trandolapril Italian Study (TRIS)," Journal of Hypertension, Vol. 17, No. 3, March 1999, pp. 439-445, XP008014000.					
	CE	Keilani, et al., "Selected aspects of ACE inhibitor therapy for patients with renal disease: impact on proteinuria, lipids and potassium," Journal of Clinical Pharmacology, United States, January 1995, Vol. 35, No. 1, pp. 87-97, XP008021110.					
	CF	Bakris, et al., "ACE inhibition or angiotensin receptor blockade: Impact on potassium in renal Failure," Kidney International, Vol. 58, No. 5, November 2000, pp. 2084-2092, XP001164193.					
	CG	Mutschler, "Arzneimittelwirkungen," WVG, Stuttgart, XP002232383, pp. 576, Col. 1, paragraph 1, Figures B4-27, Tables B4-29, pp. 579, Col. 1, Paragraph 3.					
	CH	Carlsson, et al., "Angiotensin II and the endocrine pancreas: effects on islet blood flow and insulin secretion in rats," Diabetologia, Germany, February 1998, Vol. 41, No. 2, pp. 127-133, XP001148412.					
	CI	Yusuf, et al., "Ramipril and the development of diabetes," Jama the Journal of the American Medical Association, Chicago, Illinois, Vol. 286, No. 15, 17 October 2001, pp. 1882-1885, XP008013945.					
	CJ	Yusuf, et al., "Effects of an angiotensin-converting-enzyme inhibitor, rampril, on cardiovascular events in high-risk patients," The Heart Outcomes Prevention Evaluation Study Investigators, The New England Journal of Medicine, January 2000, pp. 145-153, XP008013952.					
KW	CK	A copy of the International Search Report dated 10 August 2003 issued in corresponding international application no.: PCT/US02/33213.					
EXAMINER: WO. Wiedel				DATE: 8-15-05			